Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-Based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial

Trial Profile

Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-Based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 26 May 2016

At a glance

  • Drugs Docetaxel (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Toledo
  • Most Recent Events

    • 24 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Nov 2008 1 Dec 2008 added as the planned end date, based on information from ClinicalTrials.gov.
    • 04 Oct 2008 Interim results presented at the Annual Congress of the European Respiratory Society 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top